Serum biochemical profile in patients with decompensated heart failure with preserved ejection fraction depending on obesity
Yu. S. Timofeev,
V. A. Metelskaya,
A. A. Ivanova,
N. I. Dubovskaya,
E. A. Rogozhkina,
T. Yu. Vedenikin,
R. A. Zamyatin,
A. L. Borisova,
O. N. Dzhioeva,
O. M. Drapkina https://doi.org/10.15829/1728-8800-2025-4453
EDN: TEWGYU
Abstract
Aim. To analyze a complex of cardiac markers, adipocytokines, heat shock proteins (HSPs) and extracellular matrix remodeling biomarkers in patients with acute decompensated heart failure with preserved ejection fraction (ADHFpEF) depending on the presence and degree of obesity.
Material and methods. A total of 151 patients with ADHFpEF aged 47-95 years were divided into 2 following groups: main group — 85 patients with ADHFpEF and obesity (body mass index ≥30 kg/m2); comparison group — 66 patients with ADHFpEF without obesity (body mass index <30 kg/m2) as the comparison group. The level of biochemical blood parameters was determined using routine biochemical methods on BS800M1 (Mindray, China) and Maglumi 2000 (Snibe, China) systems, as well as by the enzyme immunoassay using a Multiskan FC photometer (Thermo, USA) and reagent kits from Vector-Best (Russia), Ray-Biotech (USA), Cloud-Clone (China), DBC (Canada) and Biovendor (Czech Republic).
Results. In patients with ADHFpEF and obesity, significantly highermedian leptin levels and leptin/adiponectin ratio were found than in patients with ADHFpEF without obesity, while adiponectin and HSP70 levels in obesity were significantly lower. The median [Q25-Q75] HSP27 concentration in morbid obesity was 4,7 [1,2-24,2] ng/ml and was statistically significantly higher than in patients with class I and II obesity — 1,3 [0,3-2,7] and 0,6 [0,3-1,3] ng/ml, respectively. In patients with ADHFpEF with epicardial fat thickness ≥5 mm, not only higher leptin concentration and leptin/adiponectin ratio were found, but also increased blood myoglobin levels.
Conclusion. We revealed a number of obesity-related serum biochemical features in patients with ADHFpEF, including differences in the main adipocytokine complex parameters, as well as cellular stress biomarkers — HSP27 and HSP70. This may indicate the involvement of obesity in heart failure pathogenesis and the pathophysiological processes in heart failure decompensation.
About the Authors
Yu. S. Timofeev
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
V. A. Metelskaya
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
A. A. Ivanova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
N. I. Dubovskaya
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
E. A. Rogozhkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
T. Yu. Vedenikin
Veresaev City Clinical Hospital
Russian Federation
Russian Federation
Moscow
R. A. Zamyatin
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
A. L. Borisova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
O. N. Dzhioeva
National Medical Research Center for Therapy and Preventive Medicine; Russian University of Medicine
Russian Federation
Russian Federation
Moscow
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine; Russian University of Medicine
Russian Federation
Russian Federation
Moscow
References
1. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) doi:10.18087/cardio.2021.4.n1628.
2. Vinogradova NG, Polyakov DS, Fomin IV. Analysis of mortality in patients with heart failure after decompensation during longterm follow-up in specialized medical care and in real clinical practice. Kardiologiia. 2020;60(4):91-100. (In Russ.) doi:10.18087/cardio.2020.4.n1014.
3. Cho D, Yoo B. Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction. Heart Fail Clin. 2021;17(3):315-26. doi:10.1016/j.hfc.2021.03.002.
4. Powell Wiley T, Ngwa J, Kebede S, et al. Impact of Body Mass Index on Heart Failure by Race/Ethnicity From the Get With The Guidelines — Heart Failure (GWTG–HF) Registry. JACC Heart Fail. 2018;6(3):233-42. doi:10.1016/j.jchf.2017.11.011.
5. Fomin I. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13. (In Russ.) doi:10.15829/1560-4071-2016-8-7-13.
6. Larina VN, Oynotkinova OSh, Larin VG, et al. Heart failure with preserved left ventricular ejection fraction: a comprehensive phenotypebased approach to diagnosis and treatment. Russian Journal of Cardiology and Cardiovascular Surgery. 2022; 15(6):627-36. (In Russ.) doi:10.17116/kardio202215061627.
7. Safiullina AA, Uskach TM, Saipudinova KM, et al. Heart failure and obesity. Terapevticheskii arkhiv. 2022;94(9):1115-21. doi:10.26442/00403660.2022.09.201837.
8. Dzhioeva ON, Timofeev YuS, Metelskaya VA, et al. Role of epicardial adipose tissue in the pathogenesis of chronic inflammation in heart failure with preserved ejection fraction. Cardiovascular Therapy and Prevention. 2024;23(3):3928. (In Russ.) doi:10.15829/1728-8800-2024-3928.
9. Paillaud E, Poisson J, Granier C, et al. Serum Leptin Levels, Nutritional Status, and the Risk of Healthcare-Associated Infections in Hospitalized Older Adults. Nutrients. 2022;14(1):226. doi:10.3390/nu14010226.
10. Kurose S, Onishi K, Takao N, et al. Association of serum adiponectin and myostatin levels with skeletal muscle in patients with obesity: A cross-sectional study. PLoS One. 2021;16(1): e0245678. doi:10.1371/journal.pone.0245678.
11. Gao Y, Bai X, Lu J, et al. Prognostic Value of Multiple Circulating Biomarkers for 2-Year Death in Acute Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med. 2021; 8:779282. doi:10.3389/fcvm.2021.779282.
12. Kobusiak-Prokopowicz M, Krzysztofik J, Kaaz K, et al. MMP-2 and TIMP-2 in Patients with Heart Failure and Chronic Kidney Disease. Open Med (Wars). 2018;13:237-46. doi:10.1515/med-2018-0037.
13. Pan W, Yang D, Yu P, Yu H. Comparison of predictive value of NTproBNP, sST2 and MMPs in heart failure patients with different ejection fractions. BMC Cardiovasc Disord. 2020;20(1):208. doi:10.1186/s12872-020-01493-2.
14. Traxler D, Lainscak M, Simader E, et al. Heat shock protein 27 acts as a predictor of prognosis in chronic heart failure patients. Clin Chim Acta. 2017;473:127-32. doi:10.1016/j.cca.2017.08.028.
15. De Lemos Muller CH, Schroeder HT, Rodrigues-Krause J, Krause M. Extra and intra cellular HSP70 levels in adults with and without metabolic disorders: A systematic review and metaanalysis. Cell Stress Chaperones. 2023;28(6):761-71. doi:10.1007/s12192-023-01368-3.
16. McDonagh T, Metra M. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2023;28(1):5168. (In Russ.) doi:10.10.15829/1560-4071-2023-5168.
17. 2020 Clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.
18. Drapkina OM, Ashikhmin YaI, Ivashkin VT. Role of chaperones in pathogenesis of cardiovascular diseases and cardioprotection. 2008;13(1):56-69. (In Russ.)
19. Tutor AW, Lavie CJ, Kachur S, et al. Updates on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2023;78:2-10. doi:10.1016/j.pcad.2022.11.013.
20. Tavallaie S, Rahsepar AA, Abdi H, et al. Association between indices of body mass and antibody titers to heat-shock protein-27 in healthy subjects. Clin Biochem. 2012;45(1-2):144-7. doi:10.1016/j.clinbiochem.2011.09.022.
21. Pugliese NR, Paneni F, Mazzola M, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23:1858-71. doi:10.1002/ejhf.2337.
22. Wu CK, Su MM, Wu YF, et al. Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients. J Clin Med. 2018;7(11):427. doi:10.3390/jcm7110427.
23. Yu M, Yang H, Kuang M, et al. Atherogenic index of plasma: a new indicator for assessing the short-term mortality of patients with acute decompensated heart failure. Front Endocrinol (Lausanne). 2024;15:1393644. doi:10.3389/fendo.2024.1393644.
24. Narusov OYu, Skvortsov AA, Protasov VN, et al. Predective copeptin significance in patients with acute decompensated heart failure. Russian cardiology bulletin. 2017;12(3):30-8. (In Russ.)
25. Teplyakov AT, Grakova EV, Kalyuzhin VV, et al. New opportunities for acute decompensated heart failure diagnostics and clinical value of growth factors: VEGF, PDGF-AB, FGF basic, tissue inhibitor of metalloproteinase-1, and lipoprotein-associated phospholipase A2. Siberian Journal of Clinical and Experimental Medicine. 2015;30(2):50-60. (In Russ.)
26. Obokata M, Reddy YNV, Pislaru SV, et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6-19. doi:10.1161/CIRCULATIONAHA.116.026807.
27. Faxén UL, Hage C, Andreasson A, et al. HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. Int J Cardiol. 2017;228:709-16. doi:10.1016/j.ijcard.2016.11.194.
28. Ramirez MF, Lau ES, Parekh JK, et al. Obesity-Related Biomarkers Are Associated With Exercise Intolerance and HFpEF. Circ Heart Fail. 2023;16(11):e010618. doi:10.1161/CIRCHEARTFAILURE.123.010618.
29. de Almeida LGN, Thode H, Eslambolchi Y, et al. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacol Rev. 2022;74(3): 712-68. doi:10.1124/pharmrev.121.000349.
Supplementary files
What is already known about the subject?
- Acute decompensated heart failure with preserved ejection fraction (ADHFpEF) is a severe life-threatening condition characterized by a high hospitalization rate and death risk, while obesity is considered one of the most important heart failure risk factors and is associated with the course severity.
- A number of biochemical markers have been described in the literature that are used to assess key pathophysiological and molecular biological processes characteristic of heart failure and obesity, such as heat shock proteins (HSP), adipocytokines, matrix metalloproteinases, however, the features of their secretion in patients with ADHFpEF with different body mass index remain poorly understood.
What might this study add?
- For the first time, a complex of cardiac markers, adipocytokines, HSPs and extracellular matrix remodeling biomarkers was simultaneously studied in patients with ADHFpEF depending on the body mass index, class of obesity, and epicardial fat thickness of.
- We showed that patients with ADHFpEF and obesity have lower HSP70 and adiponectin levels and higher leptin and leptin/adiponectin ratio levels, while HSP27 hypersecretion is characteristic of morbid obesity. Higher levels of myoglobin and leptin in ADHFpEF are associated with hypertrophy of epicardial adipose tissue.
Review
For citations:
Timofeev Yu.S., Metelskaya V.A., Ivanova A.A., Dubovskaya N.I., Rogozhkina E.A., Vedenikin T.Yu., Zamyatin R.A., Borisova A.L., Dzhioeva O.N., Drapkina O.M. Serum biochemical profile in patients with decompensated heart failure with preserved ejection fraction depending on obesity. Cardiovascular Therapy and Prevention. 2025;24(7):4453. (In Russ.) https://doi.org/10.15829/1728-8800-2025-4453. EDN: TEWGYU
Views:
239
Email this article 
